Resource use and costs of investigator-sponsored randomised clinical trials in Switzerland, Germany and the United Kingdom: a meta-research study
Alexandra Griessbach,Benjamin Speich,Alain Amstutz,Lena Hausheer,Manuela Covino,Hillary Wnfried Ramirez,Stefan Schandelmaier,Ala Taji Heravi,Shaun Treweek,Matthias Schwenkglenks,Matthias Briel,Benjamin Speich,Belinda von Niederhäusern,Lars G. Hemkens,Alain Amstutz,Benjamin Kasenda,Christiane Pauli-Magnus,Matthias Schwenkglenks,Matthias Briel,Alexandra Griessbach,Stuart McLennan,Stefan Schandelmaier,Ala Taji Heravi,Shaun Treweek
DOI: https://doi.org/10.1016/j.jclinepi.2024.111536
IF: 7.407
2024-09-22
Journal of Clinical Epidemiology
Abstract:Background Conducting high-quality randomised clinical trials (RCTs) is challenging and resource intensive. Funders and academic investigators depend on limited financial resources and, therefore, need empirical data for optimal budget planning. However, current literature lacks detailed empirical data on resource use and costs of investigator-sponsored RCTs. The aim of this study is to systematically collect cost data from investigator-sponsored RCTs from Switzerland, Germany, and the United Kingdom (UK). Methods Principal investigators were asked to share their RCT cost and resource use data and enter it into an online case report form. We assessed cost patterns, cost drivers, and specific cost items, examined costs by study phase (planning-, conduct-, and finalisation phase), compared planned with actual RCT costs, and explored differences in cost patterns across countries, medical fields, and intervention types. Results We included 93 RCTs which were initiated in Switzerland (n=53; including 8 conducted in low- and lower middle-income countries), Germany (n=22), and the UK (n=18). The median total trial cost in our RCT sample was 269,846 to $1,577,924]. The median proportion of the total costs spent for planning phase was 27.5% [IQR, 20.6 to 39.7%], for conduct phase 57.3% [IQR, 44.4%-66.3%], and for finalisation phase 12.7% [IQR, 8.5% to 19.3%] with little variation across countries. The items that contributed most to the total costs were protocol writing (7.2%; IQR 3.8% to 10.6%), data management (5.0%; IQR 2.2% to 8.1%) and follow up (4.5%; IQR 2.3% to 8.4%). Of the 66 RCTs with an available original budget, 46 (69.7%) exceeded the budget by over 50%. Use of routinely collected data to assess primary outcomes was independently associated with lower per patient- and lower total trial costs. Conclusions Over a quarter of total trial costs were incurred in the planning phase, which is typically not fully funded. Two thirds of RCTs exceeded their budget by more than 50%. Investigators and funders should consider empirical cost data to improve budgeting and funding practices.
public, environmental & occupational health,health care sciences & services